Would you trial a different TKI (vs chemotherapy) if a patient with metastatic EGFRm lung adenocarcinoma developed grade 4 pneumonitis on first line osimertinib?

Topics: Thoracic Malignancies • Medical Oncology

Answer from: Medical Oncologist at Academic Institution

Presuming patient recovered from grade 4 pneumonitis, there is precedent to switching as reported by clinicians/investigators in Japan wherein EGFR TKI-induced ILD occurs with much greater frequency in this ethnic population compared to the West. As reported by Takeda et al (Japanese Journal of...

Related Questions